{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:37:45Z","timestamp":1790728665160,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013183","name":"Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chimeric antigen receptor (CAR)-based immunotherapy has shown great potential for the treatment of both hematopoietic malignancies and solid tumors. Nevertheless, multiple obstacles still block the development of CAR-based immunotherapy in the clinical setting. In this study, we aimed to summarize the research landscape and highlight the front lines and trends of this field.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Literature published from 2001 to 2021 was searched in the Web of Science Core Collection database. Full records and cited references of all the documents were extracted and screened. Bibliometric analysis and visualization were conducted using CiteSpace, Microsoft Excel 2019, VOSviewer and R software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 5981 articles and reviews were included. The publication and citation results exhibited increasing trends in the last 20 years. <jats:italic>Frontiers in Immunology<\/jats:italic> and <jats:italic>Blood<\/jats:italic> were the most productive and most co-cited journals, respectively. The United States was the country with the most productive organizations and publications in the comprehensive worldwide cooperation network, followed by China and Germany. June, C.H. published the most papers with the most citations, while Maude, S.L. ranked first among the co-cited authors. The hotspots in CAR-based therapy research were multiple myeloma, safety and toxicity, solid tumors, CAR-engineered immune cells beyond T cells, and gene editing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CAR-based immunotherapy is a promising treatment for cancer patients, and there is an emerging movement toward using advanced gene modification technologies to overcome therapeutic challenges, especially in solid tumors, and to generate safer and more effective universal CAR-engineered cell products.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.822004","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T14:31:22Z","timestamp":1648650682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhanpeng","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixu","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjun","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsinyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of Immunoglobulin-T-Cell Receptor Chimeric Molecules as Functional Receptors With Antibody-Type Specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific Activation and Targeting of Cytotoxic Lymphocytes Through Chimeric Single Chains Consisting of Antibody-Binding Domains and the Gamma or Zeta Subunits of the Immunoglobulin and T-Cell Receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-Specific Adoptive Immunotherapy for Lymphoma Using a Chimeric Antigen Receptor With Both CD28 and 4-1BB Domains: Pilot Clinical Trial Results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110","article-title":"CD28 Costimulation Improves Expansion and Persistence of Chimeric Antigen Receptor\u2013Modified T Cells in Lymphoma Patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc Spacer Abrogates Efficacy of CD19 CAR T Cells in a Xenograft Mouse Model","volume":"22","author":"Alm\u00e5sbak","year":"2015","journal-title":"Gene Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: Chimeric Antigen Receptor (CAR) T Cells Engineered With an Inducible Cytokine to Modulate the Tumor Stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A Novel Chimeric Antigen Receptor Containing a JAK\u2013STAT Signaling Domain Mediates Superior Antitumor Effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval Summary: Tisagenlecleucel for Treatment of Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for New CAR-Based Therapies With a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race Against Cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.tips.2020.11.004","article-title":"Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy","volume":"42","author":"Cort\u00e9s-Selva","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK Cells: A Promising Cellular Immunotherapy for Cancer","volume":"59","author":"Xie","year":"2020","journal-title":"Ebiomedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An Introduction to Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Human Cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1517\/14712598.2012.674507","article-title":"Emerging Trends in Regenerative Medicine: A Scientometric Analysis Incitespace","volume":"12","author":"Chen","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/fon-2019-0810","article-title":"Global Hotspots and Future Prospects of Chimeric Antigen Receptor T-Cell Therapy in Cancer Research: A Bibliometric Analysis","volume":"16","author":"Liu","year":"2020","journal-title":"Future Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T Cell Persistence Through ICOS and 4-1BB Costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New Development in CAR-T Cell Therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T Cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive Immunotherapy for Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma Using Genetically Modified Autologous CD20-Specific T Cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK Cell Platform for Cancer Immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00259","article-title":"Bibliometric Analysis of Dendritic Epidermal T Cell (DETC) Research From 1983 to 2019","volume":"11","author":"Deng","year":"2020","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18007","article-title":"A Bibliometric Analysis of Top-Cited Journal Articles in Obstetrics and Gynecology","volume":"2","author":"Brandt","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged Survival and Tissue Trafficking Following Adoptive Transfer of CD4zeta Gene-Modified Autologous CD4(+) and CD8(+) T Cells in Human Immunodeficiency Virus-Infected Subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 Anti-CD19 CAR T-Cell Therapy in Adult Relapsed\/Refractory Acute Lymphoblastic Leukemia: ZUMA-3 Phase 1 Results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291","article-title":"A New Approach to the Adoptive Immunotherapy of Cancer With Tumor-Infiltrating Lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science (Am Assoc Adv Sci)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230705","article-title":"New Simplified Molecular Design for Functional T Cell Receptor","volume":"23","author":"Brocker","year":"1993","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T Cell Immunotherapy for Human Cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683232","article-title":"A 20-Year Research Trend Analysis of the Influence of Anesthesia on Tumor Prognosis Using Bibliometric Methods","volume":"11","author":"Luo","year":"2021","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"139r","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02630-8","article-title":"Current Trends in Cancer Immunotherapy: A Literature-Mining Analysis","volume":"69","author":"Pouliliou","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B Cell Maturation Antigen, in Patients With Relapsed or Refractory Multiple Myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T Cells Expressing an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Multiple Myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells Against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611710","article-title":"How to Combine the Two Landmark Treatment Methods\u2014Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-020-00247-8","article-title":"Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia: Who? When? Why","volume":"8","author":"Jiang","year":"2020","journal-title":"Biomark Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01529","article-title":"Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy","volume":"9","author":"Thakar","year":"2019","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy - Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of Cytokine Release Syndrome and Neurotoxicity Related to CAR-T Cell Therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.07.011","article-title":"Improving the Safety of T-Cell Therapies Using an Inducible Caspase-9 Gene","volume":"44","author":"Zhou","year":"2016","journal-title":"Exp Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0043","article-title":"A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression Upon Drug Administration","volume":"4","author":"Sakemura","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive Mitigation of CD19 CAR T-Cell Cytokine Release Syndrome Without Attenuation of Antileukemic Efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82416","article-title":"Isolation of Neoantigen-Specific T Cells From Tumor and Peripheral Lymphocytes","volume":"125","author":"Cohen","year":"2015","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13131","article-title":"Prediction and Prioritization of Neoantigens: Integration of RNA Sequencing Data With Whole-Exome Sequencing","volume":"108","author":"Karasaki","year":"2017","journal-title":"Cancer Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/med.21818","article-title":"The Antigen-Binding Moiety in the Driver\u2019s Seat of CARs","volume":"42","author":"Hanssens","year":"2021","journal-title":"Med Res Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.04.017","article-title":"Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia","volume":"25","author":"Arcangeli","year":"2017","journal-title":"Mol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual-Targeting CAR-T Cells With Optimal Co-Stimulation and Metabolic Fitness Enhance Antitumor Activity and Prevent Escape in Solid Tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2487","article-title":"A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3\u2013specific CAR T Cells in Solid Tumors","volume":"27","author":"Lei","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors","volume":"26","author":"Fuc\u00e0","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01104","article-title":"Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors","volume":"9","author":"Kosti","year":"2018","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1038\/s41467-019-12321-3","article-title":"CAR Exosomes Derived From Effector CAR-T Cells Have Potent Antitumour Effects and Low Toxicity","volume":"10","author":"Fu","year":"2019","journal-title":"Nat Commun"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","article-title":"Chimeric Antigen Receptor-Engineered Natural Killer Cells for Cancer Immunotherapy","volume":"13","author":"Yilmaz","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105695","article-title":"Chimeric Antigen Receptor (CAR)-Modified NK Cells Against Cancer: Opportunities and Challenges","volume":"74","author":"Wang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13094","article-title":"Genetic Reprogramming for NK Cell Cancer Immunotherapy With CRISPR\/Cas9","volume":"158","author":"Afolabi","year":"2019","journal-title":"Immunology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene Editing for Immune Cell Therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"172r","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T Cells Overcome Interpatient Antigenic Variability in Glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T Cells Targeting HER2 and IL13R\u03b12 Mitigate Tumor Antigen Escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular Remission of Infant B-ALL After Infusion of Universal TALEN Gene-Edited CAR T Cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Transl Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0410-x","article-title":"Advancing Chimeric Antigen Receptor T Cell Therapy With CRISPR\/Cas9","volume":"8","author":"Ren","year":"2017","journal-title":"Protein Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC Locus With CRISPR\/Cas9 Enhances Tumour Rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.822004\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T14:31:30Z","timestamp":1648650690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.822004\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2022.822004"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.822004","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"article-number":"822004"}}